Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 6/20 | 0.40 |
| ▸ | PLK4 | O00444 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 6/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904846 | 0.83 | BRD4 (0.33) | — | |
| SCHEMBL12102888 | 0.72 | GSK3B (0.50) | IGF1RPAK4PLK4AURKAAURKB | |
| SCHEMBL18166015 | 0.71 | MEN1 (0.43) | IGF1RPAK4PLK4AURKAAURKB | |
| SCHEMBL15722708 | 0.71 | PIK3C3 (0.47) | IGF1RAURKAAURKB | |
| SCHEMBL16637894 | 0.68 | ROCK2 (0.60) | SYK | |
| SCHEMBL4907625 | 0.67 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL15831719 | 0.64 | IGF1R (0.65) | IGF1RPAK4PLK4AURKAMEN1 | |
| SCHEMBL16540616 | 0.64 | IGF1R (0.64) | IGF1R | |
| SCHEMBL4908609 | 0.62 | IGF1R (0.62) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL15667945 | 0.62 | PIK3C3 (0.52) | IGF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, API5, CASP5 | IGF1R 1146/4885EGFR 2294/4885PAK4 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.